Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Questions Swirl Around US Aflibercept With Biocon Decision Imminent

West Virginia Court Decision Comes Ahead Of Key May 2024 Reg. Exclusivity End

Executive Summary

Biocon’s ongoing legal battle with Regeneron over US patents shielding Eylea was discussed by the originator at a pair of recent healthcare conferences, with a decision due any day.

You may also be interested in...

Formycon Gets Date For Aflibercept Filing In US

Formycon has announced a June 2024 FDA action date for its FYB203 proposed aflibercept biosimilar rival to Eylea, which is due to be marketed by Coherus in the US.

Sandoz Puts Aflibercept In Its Sights With Phase III Data

Sandoz is looking to move ahead with its planned filings for one of the most significant off-patent biologic opportunities in the coming years – Eylea (aflibercept).

Viatris Believes Eylea Biosimilar Candidate Is First To Reach US FDA’s Desk

Viatris provided several key updates for its biosimilar pipeline during the company’s Q3 earnings call, including for its biosimilar Eylea and Botox candidates, as well as disclosing another key early-stage asset.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts